Japan R&D Industry Presents United Front On Policy Reforms
Following pricing reforms earlier this year that industry saw as generally unfavorable, major pharma associations in Japan present a united front in calling for a broad range of policy revisions to promote an ecosystem that better fosters and rewards innovation.
You may also be interested in...
Janssen’s Japan country president says while the company is committed to pursuing innovation, from a policy angle it would like to see this adequately rewarded, given the broader societal benefits it can bring. Amid increasing competition from the rest of Asia, the executive says Japan also has the chance to take a global research leadership position through appropriate reforms.
European research-based pharma group proposes reconsideration of Japan’s revised pricing system, warning it is already affecting corporate R&D decisions and will stifle industry investment, innovation and patient access to new therapies if incentives are not improved.
Head of industry group in Japan makes personal plea at major biotech meeting for improvements to Japan’s innovation ecosystem, as government representatives say steps are already being taken to improve collaborative research and foster bioventures.